Early and Empirical High-Dose Cryoprecipitate for Hemorrhage After Traumatic Injury: The CRYOSTAT-2 Randomized Clinical Trial

Methodology: 3.5/5
Usefulness: 4/5

Davenport R, et al. JAMA. 2023 Oct 12:e2321019.

Editorial: Contemporary Adjuncts to Hemorrhage Control.

Question and Methods: In trauma patients with major hemorrhage, does early cryoprecipitate (6g fibrinogen) administration improve survival, compared to standard care?
Findings: There was no difference in all-cause mortality at 28 days (25.35 vs. 26.1%); OR 0.96 [95% CI 0.75-1.23] p=0.74
Limitations: Cross over between groups (15% of cryoprecipitate group didn’t receive any, 9% of control group received cryoprecipitate within 90mins) though per protocol analysis this didn’t impact the results.

Interpretation: Addition of early and empiric cryoprecipitate to standard care among adult trauma patients with major hemorrhage protocol activation, did not improve all cause 28-day mortality.

By: Dr. Mejbel Alazemi

JC Supervisor: Dr. Venkatesh Thiruganasambandamoorthy

Authors

Mejbel Alazemi

Dr. Mejbel Alazemi is a junior editor for the EMOttawa Blog, and is a FRCPC resident in the Department of Emergency Medicine, at the University of Ottawa.
View all posts
Hans Rosenberg

Dr. Rosenberg is an emergency physician at the Ottawa Hospital, associate professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.
View all posts
Venkatesh Thiruganasambandamoorthy

Dr. Venkatesh Thiruganasambandamoorthy is an attending physician and associate scientist at the Ottawa Hospital and Ottawa Hospital Research Institute with an particular interest in syncope and presyncope care.
View all posts